Prevalence of thrombocytopenia among Indian patients who are on chemotherapeutic drugs in five cities of India: A cross sectional descriptive study

Authors : Atul Khajuria, Parmila Malik, Jyotsana Khattri, Veeresh VG, Lalit Singh

DOI : 10.18231/j.pjms.2023.135

Volume : 13

Issue : 3

Year : 2023

Page No : 736-740

Chemotherapeutic drugs are chemical drugs used in management of cancer, these drugs are chemotoxic and has varied number of adverse effects. Thrombocytopenia is one such adverse effect, thrombocytopenia is the condition in which the platelets counts are less than few lakhs and cause the symptoms of the bleeding. The present study desiged to find the prevalence of thrombocytopenia among Indians who are on chemotherapeutic drugs.: a descriptive cross section survey design used to identify the prevalence rate of thrombocytopenia among patients who are on chemotherapeutic drugs in India the cities studied are Lucknow 268 patients, Panipath 357 patients, Sonipath 384 patients, Gohana 291 patients, Delhi 445 patients, a total 1745 patients were under chemotherapeutic drugs of which 281 patients developed thrombocytopenia, in the samples collected analyzed at various selected diagnostic centers.: The present study found that in Lucknow for 268 patients on chemotherapy 37 patients samples developed thrombocytopenia, Panipath for 357 patients on chemotherapy 76 patients samples developed thrombocytopenia, Sonipath for 384 patients on chemotherapy 68 patients samples developed thrombocytopenia, Gohana for 291 patients on chemotherapy 32 patients samples developed thrombocytopenia and in Delhi for 445 patients on chemotherapy 68 patients samples developed thrombocytopenia respectively. The overall prevalence of thrombocytopenia among patients who are on chemotherapeutic drugs is 16.01%. chemo drugs are vital in management of cancer conditions, these drugs are best currently known in reducing or killing the cancer cells, however they also carry a bag of adverse effects which hampers the wellbeing of patients hence, the knowledge and prevalence rate of thrombocytopenia in patients under chemotherapy plays a vital role in primordial prevention and better management of thrombocytopenia in its occurrence.


Citation Data